A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are published in the New England Journal of Medicine and were presented simultaneously at the American Heart Association's annual meeting.
❓ Unknown
Novel Monoclonal Antibody Therapy MAR001 Significantly Reduces Triglyceride Levels in Phase 2 Trial
Just now
November 9, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A phase 2b clinical trial has demonstrated that the monoclonal antibody therapy MAR001 can significantly lower triglyceride levels in patients within 12 weeks. The research was conducted by Mass General Brigham Heart and Vascular Institute and published in the New England Journal of Medicine. This development may have implications for healthcare advancements in Iran, particularly in managing cardiovascular health.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
13 min ago •
Unannounced Visit of Al-Zaydi to Iran Confirmed/ He Has Met with Qalibaf
18 min ago •
US Faces G7 Scrutiny on Iran and Ukraine Post Republican Midterm Losses
18 min ago •